Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 3/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | CTSA | P10619 | 1/20 | 0.35 |
| ▸ | ATP4A | P20648 | 1/20 | 0.34 |
| ▸ | ATP4B | P51164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2778983 | 0.89 | POLB (0.44) | — | |
| SCHEMBL2781640 | 0.87 | CD274 (0.39) | PLAUADORA2AADORA1ROCK2CTSA | |
| SCHEMBL2780920 | 0.85 | PLAU (0.37) | PLAUADORA2AROCK2MAPK1 | |
| SCHEMBL2783653 | 0.83 | ADRA2A (0.41) | PLAUADORA2AADORA1ROCK2 | |
| SCHEMBL2780840 | 0.81 | PLAU (0.50) | PLAUADORA2AADORA1GFERMAPK1 | |
| SCHEMBL2779067 | 0.80 | PLAU (0.42) | PLAUADORA2AROCK2MAPK1 | |
| SCHEMBL2381520 | 0.80 | ROCK2 (0.40) | ADORA2AROCK2MAPK1 | |
| SCHEMBL2782503 | 0.78 | PLAU (0.49) | PLAUADORA2AADORA1GFERMAPK1 | |
| SCHEMBL2381327 | 0.78 | KDM4E (0.47) | ROCK2MAPK1 | |
| SCHEMBL2379775 | 0.77 | HIF1A (0.40) | ADORA2AADORA1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296697-B2 | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors | ABBOTT LABORATORIES (US) | 2016-03-29 | — | — | US | disclosed |
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | HTR5A, HTR2C, HTR1E | PLAU 3291/4885ADORA2A 32/4885ADORA1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.